> Drug Discovery Report List
- Outlook for RNAi, 2007 - due to be published soon
This report provides a detailed insight into the most effective use of this novel technology in the drug discovery and development process. It puts into context where RNAi technology is being used as a tool of choice within academia and the pharma industry for functional genomic studies, drug target discovery and mechanism of action studies. The development status RNAi based therapeutics is covered in detail.
- Drug Repositioning Strategies - published July 2007
This report analyzes strategies that are currently being employed by the leading players and the associated opportunities and challenges arising from them, enabling you to understand trends in the market and optimize your R&D pipeline. Use this report to examine current approaches to drug repositioning and identify successful technologies and business models that can help your organization deliver enhanced clinical and commercial output.
>> Learn more
- Next Generation Protein Engineering and Drug Design - published Feb 2007
This report provides a detailed insight into the current market for engineered proteins and peptides, and explores the key factors of commercial success for the development of next generation products. This report also provides in-depth analysis of patenting trends and market forecasts to 2011, enabling you to exploit innovative protein engineering technology in your drug discovery process.
>> Learn more
- Biopartnering Strategies - published Dec 2006
Over the past 30 years the biotechnology industry has evolved rapidly, resulting in changes to biopartnering dynamics. Out-licensors now command greater power and leverage over the licensing of their technologies, changing the approach of out-licensing at various stages of the lifecycle and highlighting the need for biotechnology companies to adapt existing strategies to optimize this process.
>> Learn more
- Winning R&D Productivity Strategies - published Oct 2006
The need to produce novel drugs faster and more cheaply has put biopharma under intense pressure to innovate, despite rising costs and high risks. As R&D spend rises year on year, limited growth in the number of marketed drugs threatens to deepen the productivity crisis. Our new report; Winning R&D Productivity Strategies provides in-depth analysis of current issues affecting R&D, with assessment of challenges to productivity including, rising costs of drug development, attrition rates and clinical development times.
>> Learn more
- The Future of Metabolomics - published Aug 2006
Metabolomics - the new ‘omics’ - is a dynamic and emerging field, joining genomics, transcriptomics and proteomics in enabling an integrative systems biology approach to drug discovery and development. Although metabolomics is still at an early evolutionary stage it is forecast that over the next decade the biopharma industry will apply this technology more widely in drug development and data obtained will be used in drug filing and optimizing the lifecycle management of marketed drugs.
>> Learn more
- Commercial Opportunities from Biomarkers - published May 2006
High clinical development costs coupled with declining drug discovery success rates have meant that pharmaceutical companies must re-evaluate their drug development process in order to reduce attrition rates and remain competitive. Over the next decade biomarkers will change the way in which pharma companies determine the economic viability of their drug discovery process. The use of biomarkers to aid the discovery of promising products will create an enhanced understanding of the clinical development process and help to facilitate the shift towards 'personalized medicine'.
>> Learn more
- Opportunities in Stem Cell Research - published March 2006
This research analyzes the key factors impacting the commercial exploitation of adult, fetal and embryonic stem cells. This new report provides pharmaceutical companies with a clear assessment of opportunities and challenges presented to them by the stem cell market. It also provides vital insights into stem cell technologies and therapies that have already proven to be successful and analyzes those which have potential future value.
>> Learn more
- Predictive ADME and Toxicology Strategies - published March 2006
ADME and toxicology drug failures cost pharmaceutical companies up to $2 billion annually and are driving companies to seek more efficient methods of testing compounds in the area of adsorption, distribution, metabolism, excretion and toxicity. The major goal of these tests is to identify the problematic compounds early in the drug discovery process, which increases the success rate of the compounds that do make it into the later, more expensive stages of the process.
>> Learn more
- The Emerging Drug Targets Outlook - published Nov 2006
Drug targets are generally proteins. Nucleic acids are possible drug targets, and approaches such as RNA interference (RNAi) may indeed have advantages over proteins, but they have not so far been developed extensively. Protein targets consist mainly of enzymes, regulatory molecules such as cytokines, receptors for hormones or other regulatory molecules, transporters, and ion channels. Proteins that interact with small molecules are considered the most promising targets, because it is often possible to design or discover small molecule activators or inhibitors based on the natural ligands. Such substances are relatively straightforward to develop as drugs. Overall, enzyme targets account for over 50% of marketed drugs, and GPCR targets represent more than 20%, including 23 of the 100 best-selling drugs in the US.
>> Learn more
- Lead Optimization Strategies - published Sept 2005
The pharmaceutical industry has undergone considerable consolidation during the last 20 years as companies attempt to maintain double-digit sales growth and shareholder value. Strategic mergers and acquisitions have resulted in companies revitalizing their drug pipelines to replace blockbuster drugs that face patent expiration. In many cases, whilst mergers cause a period of less productive transition, significant cost-savings can be reaped and overheads reduced.
>> Learn more
- The Future of Systems Biology - published Sept 2005
This report provides a detailed insight into this complex new process and how it can be used to drive research and development in a variety of biologically-based industries. The competitive landscape of systems biology assessed in this report is supported by case studies of leading companies, enabling you to learn from their experiences and avoid the potential pitfalls. The future of pharmaceuticals lies in combination therapies and more personalized therapeutics.
>> Learn more
|
